Along with marketing approval, the FDA also awarded Epogen “orphan drug” status under an Act that provided companies with incentives to develop drugs to treat rare diseases and had approved the use of EPO for the treatment of anemia in HIV-infected patients receiving zidovudine (AZT) (Figure 1). Here, EPO is linked to anemia (phenotype).